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Many chemotherapeutic drugs have a narrow therapeutic window due to inefficient tumour cell
permeation. Supramolecular self-associating amphiphilic salts (SSAs) are a unique class of small
molecules that offer potential as next generation cancer drugs and/or therapeutic enhancement agents.
Herein, we demonstrate the cytotoxicity of seven SSAs towards both ovarian and glioblastoma cancer
cells. We also utilize the intrinsic fluorescent properties of one of these lead SSAs to provide evidence for
this class of compound to both bind to the exterior cancer cell surface and permeate the cell
membrane, to become internalized. Furthermore, we demonstrate synergistic effects of two lead SSAs
on cisplatin-mediated cytotoxicity of ovarian cancer cells and show that this correlates with increased
DNA damage and apoptosis versus either agent alone. This work provides the first evidence that SSAs
interact with and permeate cancer cell membranes and enhance the cytotoxic activity of
a chemotherapeutic drug in human cancer cells.Introduction
Cancer is a major global health problem; it is the second
highest cause of death worldwide, resulting in almost 9.9
million deaths in 2020.1 Owing to the challenges inherent in
designing diseased cell specic treatments, many marketed
drugs cause toxicity towards healthy cells.2 This leads to
a myriad of adverse health effects for the patient, including
early mortality.3 However, cytotoxic chemotherapies, such as
cisplatin remain one of the most effective therapeutic strategies
for a range of cancers, including ovarian cancer.4 However, the
use and dosage of these therapies are limited by nephrotoxicity
and both intrinsic and acquired tumor resistance to drug
action.5 Therefore, the development of agents to selectively
enhance the efficacy of these cytotoxic chemotherapies and
overcome cellular resistance mechanisms, thus lowering thenterbury, Kent, CT2 7NJ, UK. E-mail: M.D.
Kent, Canterbury, Kent, CT2 7NH, UK.
ingham, Edgbaston, Birmingham, West
ron Walden, CB10 1XL, UK
(ESI) available: These data include all
icochemical methods and supporting
erein. See DOI: 10.1039/d1ra02281d
the Royal Society of Chemistryeffective doses of a chemotherapy to be administered is of the
utmost importance.
Fig. 1 shows the structures of seven (1–7) supramolecular
self-associating amphiphilic salts (SSAs) which are membersFig. 1 Chemical structure of cisplatin and SSAs 1–7. TBA ¼ tetrabu-
tylammonium, TMA ¼ tetramethylammonium, TPA ¼
tetrapropylammonium.
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Fig. 2 Cartoon illustrating the hypothesised mode of SSA anticancer
activity, where the SSAs arrive at the cancer cell surface as self-asso-
ciated spherical aggregates (evidence provided in previously published
data).8,9 The SSAs initially interact with the external cell surface to form
a coating and are then internalised (evidence provided in Fig. 3). This
process enhances the efficacy of the cancer drug cisplatin, upon
addition after prior incubation of the cells with an SSA (evidence
























































































View Article Onlinefrom a current z70 compound library.6–8 We have previously
shown SSAs to: adopt a variety of environment dependent nano-
scale structures; act as antimicrobial agents; act as antibiotic
delivery materials and;8,9 act as antimicrobial efficacy enhancers.10
Based on these initial studies, we proposed the following SSA
mode of antimicrobial action: SSAs arrive at the cell surface in
a self-associated form (typically as spherical aggregates with
a hydrodynamic diameter z 100–550 nm in diameter), the
monomeric constituents of which then interact selectively with the
polar phospholipids present on the exterior bacterial surface such
as phosphatidylethanolamine (PE),11,12 a process which causes
membrane disruption/SSA internalization, resulting in an inhibi-
tion of bacterial growth. In healthy human cells these polar
phospholipids are more commonly conned to the inner leaet of
the cellular membrane, while neutral (e.g. phosphatidylcholine)
and zwitterionic (e.g. sphingomyelin) phospholipids are found at
the extracellular cell surface.13 This asymmetric phospholipidTable 1 GI50 values (mM) for cisplatin and 1–7 as determined by 96
hour sulforhodamine B (SRB)16 assay in A2780 and U87MG human
cancer cell lines. Error ¼ standard deviation of the mean
Compound A2780 U87MG
Cisplatin 0.79  0.4 6.41  4.7
1 44.6  19 248  22
2 278  18 395  100
3 451  38 >500
4 51.3  17 297  92
5 53.6  17 316  49
6 29.6  9.7 189  52
7 59.5  8.1 367  49
14214 | RSC Adv., 2021, 11, 14213–14217distribution is maintained through the action of ippase
enzymes.14 However, the activity of this enzyme in cancer cells is
reduced, resulting in increased expression of phospholipids such
as PE at the extracellular cell surface.15 Therefore, as illustrated in
Fig. 2, we hypothesise that the mode of SSA antimicrobial activity
could be mirrored in cancer cells, leading to the identication of
SSAs as a potential novel cancer therapy and/or as molecular
enhancers of cancer drug, in this case cisplatin, activity.Results and discussion
The GI50 values (compound concentration required to reduce
the cellular growth by 50% versus untreated cells) for SSAs 1–7
and cisplatin against A2780 ovarian carcinoma and U87MGFig. 3 Live cell imaging fluorescence microscopy images of: (a)
untreated A2780 cells; (b) A2780 cells after addition of 6 (90 mM); (c)
untreated U87MG cells; (d) U87MG cells after addition of 6 (600 mM).
Scale bar represents 10 mm.
























































































View Article Onlineglioblastoma cell lines, are given in Table 1. In all cases, the GI50
values obtained were shown to be lower for the A2780 versus the
U87MG cell line. Of the seven SSAs, 1 and 6 were shown to be
the most effective against both cell lines. However, comparison
of these GI50 values with that of cisplatin shows these SSAs to be
several orders of magnitude less effective.
The intrinsic uorescent nature of 6 enabled live cell uo-
rescence microscopy experiments, which conrmed this SSA to
both coordinate to the exterior cell surface and to become
internalized within both A2780 and U87MG cell lines (Fig. 3).
These results are analogous to those obtained for similar
studies performed with 6 in the presence of bacteria.8 Moreover,
these results support the hypothesis that SSAs have the poten-
tial to enhance permeability of the cancer cell membrane
towards a subsequently administered chemotherapeutic agent,
synergistically increasing anticancer efficacy. To verify this, two
lead SSAs (1 and 6) identied from the GI50 studies (Table 1),
were chosen to investigate any potential SSA:cisplatin syner-
gistic anticancer effect against the A2780 cell line, to which the
greatest SSA anticancer activity was demonstrated.
As 1 and 6 were to undergo investigation towards co-
treatment applications with cisplatin, a range of physicochem-
ical SSA : cisplatin 1 : 1 co-formulation studies were performed
and conrmed that any resultant co-formulated self-associated
nanoscale aggregates retained a similar size and stability to
those of SSAs previously reported.7,17
An overview of results obtained from these studies can be
found in Table 2. For a detailed discussion of the effects of
cisplatin addition to the self-associated aggregates formed with
1 at 298 K in a H2O (or D2O)/5% ethanol solution, please see our
previous work in this area.10 However, interestingly although
the addition of cisplatin increases the proportion of the SSA to
become incorporated into the larger self-associated structures
of both 1 and 6 (quantitative 1H NMR), it has opposite effects on
the size (hydrodynamic diameter – DH, obtained from DLS
measurements), stability (obtained from zeta potential
measurements) and critical micelle concentration (CMC)
values, when compared to the values obtained for 1 and 6 alone.
In summary the self-associated aggregate structures obtained
with 1 increase in size and are destabilised upon the addition of
cisplatin, however, the self-associated aggregate structuresTable 2 Where an SSA and cisplatin were present as a co-formulation, th
see Fig. S7–S25 (see ESI). CMC, DLS and zeta potential data were obt
formulation (0.56 mM) at 298 K, except for CMC studies that were perf
obtained for a D2O/5.0% EtOH solutions of an SSA or 1 : 1 cisplatin co-fo
compound to become NMR silent, and thus adopt solid like properties as
associated aggregates. All quantitative 1H NMR experiments were cond
obtained from DLS intensity particle size distribution peak maxima
Compound
Quantitative 1H NMR (%)
SSA anion SSA cation
1 only 51 (ref. 7) 50 (ref. 7)
1 + cisplatin 65 (ref. 10) 83 (ref. 10)
6 only 10 (ref. 7) 8 (ref. 7)
6 + cisplatin 63 85
© 2021 The Author(s). Published by the Royal Society of Chemistryobtained with 6 decrease in size and are stabilised upon the
addition of cisplatin. We hypothesise that this is due to the
differences in the substituted phenyl ring systems of these two
SSAs, which alter the way in which the anionic component of 1
and 6 interact with the cisplatin co-formulant during self-
associative aggregate formation. It is also possible that these
SSA, cisplatin interactions are in-part responsible for any
symbiotic enhancement in anti-cancer activity.
Following this physiochemical investigation, the synergistic
cytotoxic effects of these SSA/cisplatin combinations were
determined using the Chou-Talalay method.18 Chou-Talalay
analysis yields a combination index (CI) where, for this study;
if CI > 1.05 the drug combination is antagonistic; if CI ¼ 0.95–
1.05 the effects of the drug combination is additive, and where
values of CI < 0.95 are indicative of synergy. Building on our
results from previous SSA combination therapy investigations,
the SSA to be investigated was preincubated with the A2780 cells
for one hour before the cisplatin was introduced to the cell
culture. This procedure has previously been shown to be the
most effective in inducing synergy between the SSA and
a second therapeutic agent, such as cisplatin.10
As summarized in Fig. 4, at the highest concentrations of
cisplatin or SSA used, these combinations yielded antagonistic
or additive anticancer effects. Interestingly, at lower concen-
trations of both cisplatin and SSA, synergism was observed. The
maximum synergy for cisplatin and 1 was observed at 0.15 mM
and 1.25 mM respectively, yielding CI¼ 0.531. Similar synergism
was displayed between cisplatin and 6; CI ¼ 0.541 at concen-
trations of 0.07 mM of cisplatin and 2.5 mM of 6. However,
a limitation of this method is that at the lowest concentration of
either drug used, bothmust still exhibit a cytotoxic cell effect. As
such, a modied assay was performed, using a lower concen-
tration range of 1 whilst maintaining the concentration of
cisplatin. Whilst 2 mM and 4 mM of 1 had minimal effects on cell
growth alone (Fig. S26†), they enhanced the activity of cisplatin,
which correlates with the synergistic effects shown in Fig. 4 for
combining 2.5 mM and 5 mM of 1 with cisplatin. In contrast, 0.2
mM and 0.8 mM of 1 antagonised the growth inhibitory effects of
cisplatin. This indicates that the synergistic activity of 1 with
cisplatin is dose-dependent.ey have been supplied in a 1 : 1 molar ratio. For processed data please
ained for a H2O/5.0% EtOH solutions of an SSA or 1 : 1 cisplatin co-
ormed at a variety of concentrations. Quantitative 1H NMR data were
rmulation (5.5 mM) at 298 K. Here % values represent the proportion of
this proportion of molecular species are incorporated into larger self-
ucted with a delay time (d1) of 60 s. Average DH measurements were
Zeta potential (mV) DH (nm) CMC (mM)
67 (ref. 10) 142 (ref. 7) 10.4 (ref. 7)
42 (ref. 10) 161 (ref. 10) 3.3 (ref. 10)
44 (ref. 10) 300 (ref. 7) 0.5 (ref. 7)
53 240 2.0
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Fig. 4 CI values obtained for 1 and 6 pre-incubated with A2780 cells
for one hour before addition of cisplatin and then 96 hour incubation,
followed by SRB assay. Each assay comprised n¼ 3 technical replicates
and is representative of three independent experiments. 0.30–0.70 ¼
synergism; 0.70–0.85 ¼ moderate synergism; 0.85–0.95 ¼ slight
synergism; 0.95–1.05 ¼ additive; >1.05 ¼ antagonism.
Fig. 5 Western blot of A2780 cells treated with high (approx. 10 
GI50) and low (GI50) concentrations of 1 and cisplatin, after 24 hours

























































































View Article OnlineTo ensure the suitability of these SSAs (1–7) as potential drug
efficacy enhancers, preliminary toxicity studies were also con-
ducted against normal human dermal broblasts. Using both
conuency and cell viability assays it was determined that the
inherent cytotoxicity of these compounds would not inhibit SSA
use towards these applications, as all SSAs displayed no
signicant effect in these assays, even at concentrations 10-fold
higher than those concentrations at which synergy was
observed (Fig. S27 and S28†).
Finally, to gain greater insight into the synergistic mode of
action of SSAs, western blot analysis was performed on lysates
prepared from A2780 cells treated with either 1 or cisplatin
alone at high (10  GI50) and low (1  GI50) concentrations and
in combination. Several cellular proteins were analysed to
evaluate effects on key intracellular signalling pathways. These
were; cleaved-PARP (PARP C), a cellular indicator of apoptosis,19
the cell signalling kinases ERK and AKT, and gH2AX,
a biomarker of DNA damage.20
PARP C production in response to 1 alone is comparable to
controls, suggesting that at the concentrations shown, 1 does
not induce apoptosis. Cisplatin alone induced apoptosis (Fig. 5)
but interestingly, the combination of 1 and cisplatin shows an
increase in PARP C levels compared to that of cisplatin alone,
supporting the hypothesis that the SSA compoundsmay be used
to enhance cancer drug efficacy. This decrease of effective dose
is crucial towards reducing the systemic toxicity inherent in
many cancer therapies. Compound 1 alone (but not cisplatin)
induced phosphorylation of AKT, an indicator of AKT activa-
tion, but this was not further enhanced when 1 and cisplatin
were combined. Both compounds had limited effects on phos-
phorylated ERK, an indicator of ERK activity but there was
a strong induction of ERK activation when 1 and cisplatin were14216 | RSC Adv., 2021, 11, 14213–14217combined. Strong ERK activation has been reported to correlate
with apoptosis.21 Interestingly, the combination of low cisplatin
with high 1 showed a higher gH2AX signal compared to low
cisplatin alone, indicative of a synergistic effect of 1 on cisplatin
mediated DNA damage.Conclusions
In summary, reducing the effective dose of commonly used
anticancer agents is a crucial challenge in medicine, to
diminish the potentially life-threatening side effects that are
a result of current dosing strategies. SSAs 1 and 6 have shown
promise as agents that increase the efficacy of cisplatin and
offer a potential platform for the targeted delivery of other
therapeutics. These investigations remain ongoing within our
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